Recon Regulatory Top Stories Lipogems Announces Last Patient Enrolled in the U.S. FDA IDE Arise Study for the Treatment of Knee Osteoarthritis byTim AllenApril 10, 2024
Recon Regulatory Top Stories Lipogems Announces First Patient Enrolled in the Second U.S. FDA IDE Study for the Treatment of Knee Osteoarthritis byTim AllenApril 8, 2024
Financial Top Stories Lipogems Raises €12.5M ($13.2M) to Accelerate the Expansion in Knee Osteoarthritis byJosh SandbergDecember 26, 2022
OSN Premium Recon Surgeon Voice Minimum Clinically Important Difference in Knee OA: A Deep Dive byJosh SandbergSeptember 6, 2019
